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Abstract
In prostate cancer (PC), increasing evidence suggests
that androgen receptor (AR) signalling is functional
under conditions of maximal androgen blockade. PC
cells survive and proliferate in the altered hormonal
environment possibly by interactions between growth
factor–activated pathways and AR signalling. The
present review article summarizes the current evidence
of this crosstalk and focuses on the interactions among
the ErbB receptor network, its downstream pathways,
and the AR. The potential role of this crosstalk in the
development of androgen independence and in relation
to antiandrogen therapy is discussed. Such interac-
tions provide insight into possible complementary or
additional strategies in the management of PC.
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Introduction
Prostate cancer (PC) is the commonest cancer affecting
men in the western world. The number of new cases of PC
registered in England and Wales (age-standardized)
increased by 104% from 1971 and 1993, whereas the
number of deaths increased by 38% between 1971 and
1998 [1]. In the year 2000, there were an estimated 180,400
new cases and 31,900 deaths in the United States [2].
Conventional therapies involve surgical or pharmacological
castration [clinically referred to as maximum androgen
blockade (MAB) when combined with antiandrogen therapy]
with the intent of maximally diminishing the availability and
action of androgen on the androgen receptor (AR). Over
time, the PC cells overcome the need for androgen as a
survival, growth, and differentiating factor and become
androgen- independent (AI ) [3,4 ]. Evidence from xenograft
models and clinical material indicates that this change to AI
growth could result from either the outgrowth of a preexisting
(pretreatment) AI clone or adaptive responses to androgen
deprivation, which allow the evolution of AI clones [5,6 ].
Under conditions of MAB, autocrine growth factor loops could
enhance growth and mitogenic signalling through the
activation of tyrosine kinase–coupled receptors and sub-
sequently second messengers such as mitogen-activated
protein kinase (MAPK), phosphoinositide 3-kinase (PI3K),
and other effector pathways.
In the last decade, it has become clear that signalling
pathways are not simply linear sequences of interactions
downstream of an activated receptor. Growth factors
appear not to act independently of the AR in the prostate.
Crosstalk between these signal transduction pathways has
been implicated in maintaining PC survival in an androgen-
poor environment [7 ]. In this review, evidence demonstrat-
ing the potentially important crosstalk mechanisms that
bypass classical androgen dependence is presented.
AR
The AR is a member of the nuclear receptor superfamily
of transcription factors [8 ]. It can be localized to the
cytoplasm or nucleus and its topographic localization is a
reflection of its functional state (active / inactive). In its
inactive state, AR associates with heat shock proteins
(hsp70 and hsp90) [9,10]. In the absence of ligand,
cytoplasmic AR is degraded. In the presence of the ligand,
testosterone, and its more potent derivative dihydrotestos-
terone (DHT), the AR–hsp complex is disrupted and the
AR undergoes conformational change that allows phos-
phorylation, dimerization, and translocation of the more
stable ligand–receptor complex to the nucleus [11,12]. In
the nucleus, the dimerized AR–ligand complex interacts
with coactivator molecules (e.g., ARA54, ARA70) [13] and
initiates gene transcription of androgen- regulated genes
by binding to specific androgen response elements
(AREs). (The different states of the AR and its localization
are illustrated in Figure 1, A and B. ) The gene activation
pathways initiated by androgens impact upon the pro-
cesses of prostatic cellular proliferation, survival, and
differentiation [14].
AI growth may be attributed to secondary genetic
mutations, which allow the AI PC cells to survive and
proliferate despite the paucity /absence of androgen and
imply that signalling through the AR is no longer active
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[15–17]. However, in nearly all cases of AI PC, the
persistent expression of AR and of androgen-regulated
genes such as PSA indicates that AR signalling is not always
bypassed but is indeed functional and active [7].
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Augmentation of AR-mediated signal at lower androgen
levels can occur by amplification of the AR gene itself. AR
gene amplification was observed in 30% of recurrent PC
tumor specimen after androgen deprivation therapy [18–23].
AR hypersensitivity and increased AR protein stability have
also been implicated in AI PC progression [24]. Several
in vitro studies on human PC cell lines have shown that
mutations in the AR can make the receptor ‘‘promiscu-
ous’’— whereby the AR can be activated by a number of
different ligands such as testosterone, DHT, estrogen,
progesterones, and the adrenal androgen dihydroepian-
drosterone (DHEA) [25]. To complicate matters further,
antiandrogens such as flutamide, hydroxyflutamide, and
bicalutamide can also activate mutant AR [26]. These
studies suggest that AR mutations in PC may provide a
survival advantage for AR-mutated clones in response to
treatment with antiandrogens as flutamide [27,28]. In
clinical PC, AR mutations have been observed [29,30]
and are thought to be the most likely explanation for the
‘‘antiandrogen withdrawal syndrome.’’ This syndrome is
a well -established phenomenon in PC where a subset
of patients will benefit from withdrawal of antiandrogen
hormonal therapy and exhibit decreasing PSA values and
clinical improvement [31]. Other researchers have reported
that antiandrogens, hydroxyflutamide, bicalutamide, cypro-
terone acetate, RU58841, and other compounds such as
genistein and RU486, can promote the interaction between
AR and its coactivator, ARA70, in a dose-dependent
manner [32]. Increased expression or mutations in AR
coactivators can activate the AR in the absence of DHT
[e.g., cofactor ARA70 specifically conferred the androgenic
effect from 17 b -estradiol (E2) and hydroxyflutamide to
AR] [33,34].
An alternative model of AR activation in the setting of
MAB involves nonsteroid receptor signal transduction
pathways [35]. AR can be activated in a ligand- independ-
ent manner by a number of growth factors including
insulin- like growth factor -1 ( IGF-1), epidermal growth
factor (EGF), keratinocyte growth factor (KGF), and
interleukin-6 ( IL-6). Each of these has been shown to
transcriptionally activate an androgen-responsive reporter
construct in the absence of ligand or synergistically in
conjunction with androgens. The mechanistic details are,
however, unknown [36–38]. The effect exerted by growth
factors on the AR suggests that these signalling pathways
are not mutually exclusive. They point towards the
existence of crosscommunication between ligands, at the
level of their cognate receptors or through their intracellular
downstream kinase cascades, and the AR. This allows
the emergence of AI cells, which can survive and
proliferate under androgen ablation, leading to recurrence
and metastasis [7,37].
Data on the importance of the interaction between
polypeptide growth factors like EGF and the ErbB network
of receptors (or their secondary mediators) with the AR in
favor of PC survival are now rapidly emerging. This article
reviews these interactions and focuses on their potential role
in promoting AI growth.
AR and the ErbB Receptors
ErbB receptors are typical receptor tyrosine kinases acti-
vated downstream of EGF and EGF- like ligands. They
include four members: EGF receptor EGFR/ErbB1, ErbB2
(or HER2/Neu), HER3/ErbB3, and HER4/ErbB4. All EGFR
family members are characterized by a modular structure
consisting of an extracellular ligand binding domain, a
transmembrane region, and an intracellular part harboring
the highly conserved tyrosine kinase domain. Ligand binding
induces the formation of homodimers or heterodimers and
the phosphorylation of tyrosine residues, which serve as
docking sites for a variety of signal transducers (Figure 1, A
and B ) [39,40]. This family of receptors plays a critical role in
the proliferation, migration, survival, and differentiation of
target cells. Dysregulation of signalling by the ErbBs has
been implicated in the pathogenesis and progression of
human cancers [39,40].
ErbB1/EGFR
EGF is a mitogen required for normal prostatic epithelial
cell growth and is present in large amounts in human
prostatic fluid [41,42]. mRNA and protein expression of its
receptor, EGFR, have been demonstrated in human PC,
benign prostatic hyperplasia (BPH), and normal prostate
Figure 1. (A ) The interaction between the AR and the ErbB /MAPK pathway. Parallel pathways activated by androgen and the ErbB receptor intersect at several
levels. Following hormone binding in the cytoplasm, the AR–hsp–containing complex is dissociated and the steroid receptor is rapidly translocated to the nucleus. In
the nucleus, AR dimerizes and binds to the DNA double helix at specific sequences called AREs. The DNA-bound AR dimer recruits a multiprotein complex
containing members of the basal transcription machinery and other coactivators or corepressors (not shown ), which control the transcriptional AR response. AR is
then dissociated from the DNA and shuttled back to the cytoplasm where it can reassociate with hsp or ligand. Growth factors initiate signalling by binding to and
sequentially activating the ErbB receptors, adaptor molecules like Grb2 and Sos, and the GTP exchange factor Ras. This in turn activates the three - tiered MAPK
cascade. Crosstalk may occur in the cytoplasm, for example, when AR complexes with Shc /Src ( two adaptor molecules recruited by activated receptor tyrosine
kinases ) to activate the MAPK pathway, leading to phosphorylation of ERK. Alternatively, ErbB2 activates the AR through ERK phosphorylation at Ser514, thereby
suggesting an influence of these two pathways on each other. c - Jun is activated downstream of MEKK, which enhances the homodimerization of AR with DNA and
consequently the AR response to androgen. The requirement for AR in MEKK1 - induced apoptosis is not shown in this figure. (B ) The interaction between AR and
ErbB /PI3K /Akt. Similar to (A ), ligand binding of the AR initiates dissociation from hsp, phosphorylation, and dimerization. Growth factors activate ErbB2 /ErbB3
complex and recruit PI3K, which produces 3 0 - phosphoinositides (PIP3 ) and recruits PDK1 and Akt, resulting in their activation. Akt then inactivates a variety of
proapoptotic molecules including Bad, caspase 3, GSK-3, and the forkhead transcription factors (FKHR ). In addition, Akt targets the AR and phosphorylates it at
Ser210 and Ser790. This phosphorylation promotes PC cell survival by controversial mechanisms (marked by the question marks ). Some workers hypothesize that
this is through activation of AR transcription. Alternatively, it may protect the cells from androgen - induced apoptosis through ubiquitylation and degradation of the AR
within an Akt /Mdm2 /AR complex. Another mechanism of AR activation by Akt is through GSK-3 inactivation and nuclear accumulation of  - catenin. In the
cytoplasm, AR rapidly activates PI3K and increases intracellular PIP3 by an as yet unknown mechanism. PTEN, the negative regulator of this pathway, is not shown
in this figure.
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[43,44]. Transforming growth factor -a (TGF-a ) is another
ligand for EGFR. The existence of a stimulatory autocrine
loop involving EGF, TGF-a, and EGFR has been suggested
from in vivo observations in high-grade prostatic intra-
epithelial neoplasia (PIN) and PC. These lesions showed a
higher expression of membranous EGFR, ErbB2, and
cytoplasmic TGF-a than low-grade PIN or BPH [45]. This
stimulatory loop appeared to be important in the growth of
three human PC cell lines: PC-3, LNCaP, and DU145. The
DU145 cell line was apparently dependent on this autocrine
loop for cell proliferation [46]. The importance of the EGFR in
promoting the survival of PC cells was demonstrated in the
CWR22 xenograft model of PC, in which castration was
associated with an initial reduction in EGFR expression.
EGFR returned to comparable or higher levels following the
administration of androgen or in relapsed AI tumors
(CWR22R) [47].
DHT and EGF are thought to play complementary roles in
regulating the proliferation of prostate cells. The combination
of DHT and EGF has been shown to enhance the
proliferation of the MDA PC2a and MDA PC2b human PC
cell lines through a convergent stimulatory mechanism. This
promoted progression through the cell cycle by increasing
cyclin-dependent kinase-2 (CDK2) activity and accelerat-
ing the downregulation of the CDK inhibitor p27kip1 compared
to either ligand alone [48]. In addition, an interactive
stimulation of EGFR synthesis by DHT [47–51] and of AR
synthesis by EGF [48] has been described in several
androgen-sensitive PC cell lines. DHT increased both EGFR
expression and receptor– ligand affinity, resulting in
increased EGF binding and an enhanced mitogenic
response to EGF [47–51]. This effect of DHT can be
blocked by the AR antagonist bicalutamide, which indicates
that these effects require the AR [47].
ErbB2 (HER2/Neu)
ErbB2 is one of the best -studied genes involved in human
malignancy. In PC, ErbB2 is considered a potential surrogate
biomarker for screening chemopreventive agents in short -
term Phase II trials [52,53]. Unlike other members of the
ErbB family, ErbB2 has no known ligand and is the preferred
heterodimerization partner within the EGFR family. Hetero-
dimers containing ErbB2 induce signals with the strongest
biological activity [39]. EGFR and ErbB2 serve as receptors
for EGF [40] and so they are likely to be involved in an
interaction between the EGF and AR signalling pathways.
Studies of the role of ErbB2 in PC remain inconclusive.
Previous work has shown widely divergent levels of ErbB2
expression in primary PC, probably owing to methodological
differences in the studies. Some authors have demonstrated
ErbB2 protein overexpression and/or gene amplification in a
subset of PC patients and in premalignant lesions [54–58].
ErbB2 protein was expressed at statistically significant
higher levels in PC treated by androgen deprivation therapy
compared to untreated cancer [57,59]. On the other hand,
some investigators have not found overexpression of ErbB2
in PCs [60] and most have not shown amplification of the
ErbB2 gene [59,61,62]. Several authors have suggested
that elevated serum levels of the extracellular portion of
ErbB2 in patients with metastatic PC provide further
supporting evidence of its potential role [63,64]. Using the
LAPC-4 mouse xenograft model, Craft et al. [65] showed
that AI sublines of human PC xenografts expressed higher
levels of ErbB2 than androgen-dependent sublines. They
also showed that overexpression of ErbB2 confers AI growth
to the androgen-dependent LNCaP cell line. In the absence
of androgen, overexpression of ErbB2 activated the tran-
scription of prostate specific antigen PSA (a process that
requires a functional AR but is not inhibited by the
antiandrogen bicalutamide) [65]. The failure of bicalutamide
to block PSA induction by ErbB2 is consistent with clinical AI
PC and indicates that ErbB2 interacts with the AR pathway
distal to the interaction between androgens and AR.
The biochemical mechanisms of this crosstalk are
unclear, but the failure of ErbB2 to activate a single high-
affinity AR binding site points either to the involvement of an
intermediate protein, or that ErbB2 may optimize AR function
by activating Ras and other signalling pathways (Figure 1A ).
Ras proteins are molecular switches with the ability to
interact and activate several effector molecules. Among
those, Raf-1 kinase, PI3K, and Ral -GDS are the best
characterized. Raf activates the mitogenic MEK/ERK
kinases pathway, whereas PI3K regulates the PKB/Akt
cascade, involved in the control of proliferation, metabolism,
and apoptotic responses (both pathways are discussed in
detail below and outlined in Figure 1, A and B, respectively ).
Yeh et al. [66] demonstrated ErbB2 activation of the AR
through activating the MAPK pathway as well as promoting
the interaction of AR and ARA70 coactivator. ErbB2 over-
expression thereby favors AR activation at very low levels
of androgen.
ErbB2 has also been involved in signalling downstream of
other ligands such as IL-6. As previously mentioned, IL-6 is
a nonsteroidal activator of the AR whose level is frequently
elevated in sera of patients with metastatic PC [67]. Through
a novel mechanism that involves the heterodimerization of
the IL-6 receptor and ErbB2, IL-6 activated both ErbB3 and
MAPK in LNCaP cells [68].
ErbB3/HER3 and ErbB4/HER4
Neu differentiation factor /heregulin (HRG) belongs to a
family of polypeptide growth factors that bind to receptor
tyrosine kinases ErbB3 and ErbB4. HRG binding induces
ErbB3 and ErbB4 heterodimerization, activating downstream
signal transduction. ErbB3 differs from other ErbB family
members in that it possesses diminished kinase activity and
is largely dependent upon other ErbB kinases, in particular
ErbB2 [39,69].
HRG is present in normal human adult prostate and BPH,
where it may function as a paracrine physiological differ-
entiation factor [70,71]. Analysis of clinical PC specimens
indicates that overexpression of ErbB3 has been linked to a
less favorable prognosis [72]. In PC cell lines, HRG inhibited
the growth of AR-positive but not AR-deficient cells [71].
The exact sites of crosstalk between HRG and AR signalling
pathways remain to be elucidated. However, the fact that
102 AR and ErbB Receptor Signal Transduction Crosstalk El Sheikh et al.
Neoplasia . Vol. 5, No. 2, 2003
only AR-positive PC cells appear to be influenced by HRG
supports the concept that the physiological function of HRG
on prostatic cells is optimal in the presence of AR.
Ebp1 is a recently identified ErbB-3 binding protein that
possesses an important motif, which mediates interactions
with nuclear hormone receptors and is thought to provide a
link between the ErbBs and AR. Ebp1 has been shown to
bind to AR in vitro and in vivo. It inhibited ligand-mediated
transcriptional activation of AR-regulated genes such as the
PSA growth of AR-positive LNCaP cells [73].
Reports on the ErbB4 in the prostate are few. ErbB4
protein is strongly expressed by normal prostate luminal
cells. Only 23% of PC specimens and none of the PC cell
lines examined so far expressed ErbB4 [71]. More inves-
tigations into the role of ErbB4 in the prostate are required.
Interactions between the AR and the ErbB receptors are
summarized in Table 1.
AR and Signal Transduction Pathways
Steroid receptors are phosphoproteins. Phosphorylation of
human steroid hormone receptors is generally believed to
positively or negatively modify their transcriptional activity
rather than act as an on–off switch. Phosphorylation–
dephosphorylation events are influenced by ligand binding,
which may affect both ligand-dependent and ligand-
independent receptor functions [74]. Such events may
predominantly serve to fine- tune aspects of receptor
regulation, perhaps by influencing the integration of signals
from other pathways or by modulating the subcellular
localization, trafficking, and degradation of receptor pro-
teins [74–76]. Analogous to other members of the steroid
receptor superfamily, AR is highly phosphorylated [77] and
therefore sensitive to growth factor– initiated signalling
pathways. Site-directed mutagenesis has confirmed three
phosphorylation sites on the AR: two in the N- terminal
domain (Ser81, Ser94) and one in the hinge region
(Ser650) [78]. Identification of these AR phosphorylation
sites allows the study of protein kinase(s), which may be
involved in the phosphorylation of AR under conditions of
androgen ablation.
MAPKs
MAPKs are mediators of cellular responses to many
extracellular stimuli [79]. At least three subgroups have
been identified: extracellular signal–regulated kinase
(ERK), c-Jun N-terminal protein kinase (JNK), also known
as stress-activated protein kinase (SAPK), and p38/HOG
(reactivating protein kinase). These three MAPK subfamilies
represent similar, yet distinct protein kinase cascades.
Each consists of a module of three cytoplasmic kinases:
a MAPK kinase kinase (MAPKKK), a MAPK kinase
(MAPKK), and the MAPK itself [80–82].
The best understood MAPK signal transduction pathway
in mammalian cells is that formed by the Raf /MEK/ERK.
Proliferative signals provided by growth factors activate the
MAPK pathway through their cognate receptors. Receptor
tyrosine kinase activation and phosphorylation recruit adap-
tor proteins Grb2 and Sos. Sos is a GTP exchange factor,
which activates the small G-protein Ras. This in turn
activates the MEK kinase (MEKK) Raf, the MAPK/ERK
(MEK) kinase, and subsequently MAPK/ERK [79,82]. ERK
Table 1. A Summary of the Major Interactions between the AR and ErbB -Mediated Signalling.
Interaction with the AR Effect on cell
EGF /EGFR EGF augments DHT and AR signalling, and
stimulates AR synthesis [ 48 ]
Enhanced proliferation and cell cycle progression
DHT stimulates EGFR synthesis [ 47–51 ] Enhanced mitogenic response to EGF
ErbB2 Transcriptional activation of PSA [65 ], enhancement
of AR coactivator binding [ 66 ], activation of
MAPK signalling downstream of IL - 6 [ 68 ]
Ligand - independent activation of AR,
which promotes survival and proliferation of
PC in the androgen -depleted environment
HRG/ErbB3 HRG acts on AR positive cells only [ 71 ] possibly
through ErbB -3 binding protein Ebp1, which binds
to AR in vitro and in vivo [ 73 ]
Inhibition of ligand -mediated transcriptional activation of
AR and reduced growth of AR -positive cells
MAPK /ERK2 Activation of AR transcription downstream of ErbB2
and IL - 6 [ 66 ], phosphorylation of the AR at
Ser514 [66 ] and SRC-1 [93 ]
Optimal ligand -dependent and ligand - independent
activation of the AR
AR activates MAPK in a complex with Src /Shc [90,91 ]. A rapid nongenomic effect that cannot be inhibited by
antiandrogens [89 ]
MEKK1 Transcriptional activation of AR [94 ] possibly through
its downstream target c - Jun, which interacts with
the DNA binding domain / hinge region of AR [96,97 ]
Potentiation of the functional interaction between N- terminus
and C - terminus of AR to enhance DNA binding and
gene transcription
Activates apoptotic pathways only in AR-expressing
cells [ 94 ]
Apoptosis of PC cells
Akt Phosphorylates AR at Ser210 and Ser790, which
either activates transcription of AR - regulated genes
in the absence of androgens [109,114 ]; alternatively,
phosphorylation and inactivation of GSK-3b increased
nuclear levels of b - catenin, which elevates AR
activity [ 118 ]
Increased survival of PC cells in the absence of androgen
Repression of AR transcriptional activity [ 119 ] by
increasing AR degradation in a complex that includes
Akt, Mdm2, and the AR [122 ]
Increased survival of PC when androgen favors PC apoptosis
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activity is increased in many human tumors including PC.
Both ERK expression and activation are postulated to
mediate important roles in the initiation and progression of
PC [83,84]. In the AI PC DU145 cell line, the constitutive
phosphorylation of ERK2, a hallmark of MAPK activation has
been reported and can be blocked by several EGFR
inhibitors [85].
The MAPK pathway is also a target of steroid receptors
(Figure 1). In addition to being transcription factors, both
estrogen receptor (ER) and AR activate MAPK [86–90].
In a complex with Src/Shc, AR activates ERK-1 and ERK-
2 in PC cells to stimulate their proliferation [90]. This rapid
effect of the AR (within 2 minutes) [89,91] is distinct from
its genotropic effects. It may be effected by less fully
developed or broader receptor conformations initiated by
brief association with the ligand [91]. In nonprostatic cells,
the ligand binding domains of ER and AR were sufficient to
stimulate an anti–apoptotic response through Src/Shc/
ERK, a response which was eliminated by nuclear
targeting of the receptor [91]. The activation of ERK by
AR is specific for this class of kinases and cannot be
inhibited by antiandrogens [89]. These findings imply that
the current therapeutically available antiandrogens may not
be totally effective in abrogating all androgenic activities in
target cells.
Conversely, MAPK pathways were shown to activate
the AR and thus mimic androgen signalling in the
androgen-depleted environment [92]. MAPK was required
for both ligand-dependent and ligand- independent activa-
tion of the AR downstream of ErbB2 and IL-6 [65,66,93].
ErbB2 was shown to induce androgen-dependent gene
activation in the absence of ligand through the phosphor-
ylation of AR in the N-terminal segment at amino acids
511–515 by MAPK (ERK2) [66]. The phosphorylation of
steroid receptor coactivator -1 (SRC-1) by MAPK was also
required for optimal ligand- independent activation of the
AR by IL-6 [93].
In contrast to the Raf /MEK/ERK pathway, MEKKs
comprise a family of related serine–threonine protein
kinases that regulate MAPK signalling pathways, leading to
c-Jun N terminal kinase and p38. These MAPK pathways
are induced by cellular stress, inflammatory cytokines, and
G-protein–coupled protein agonists. They have been
implicated in apoptosis, oncogenic transformation, and
inflammatory responses in various cell types. MEKK1
mediates Ras-dependent activation of JNK cascades by
growth factor receptors through an association with Grb2
[82] (Figure 1). The link between MEKK1 and AR signalling
is contradictory and puzzling. The MEKK1 pathway may
contribute to the progression of PC to AI by modulating the
activation of AR and its transcriptional response to ligands
[94]. A constitutively active MEKK1 stimulated natural and
artificial androgen response promoter templates in an AR-
dependent manner and induced transcriptional activation of
AR-regulated genes in the absence of androgens. Further-
more, a dominant negative mutant of MEKK1 impaired the
activation of the AR by androgen [94]. The molecular basis
of this crosstalk is unclear. MEKK1 possibly activates
signalling cascades (such as c-Jun) that indirectly lead to
posttranslational modifications of the AR and affect its
function. Homodimerization of the AR and other steroid
receptors is required for these transcription factors to bind
DNA. This homodimerization is thought to result from an
intramolecular or intermolecular interaction between the
amino and carboxyl termini of the receptor [95]. The
downstream target of MEKK1/JNK, c-Jun, interacts with
the DNA binding domain/hinge region of AR to potentiate the
functional interaction between N-terminal and C- terminal
and enhance AR DNA binding and gene transcription
[96,97].
MEKK1 induced apoptosis in diverse non–AR-express-
ing cells in response to stress or DNA-damaging agents
[82]. Interestingly in PC, MEKK1 induces an apoptotic effect
only when the AR signalling pathway is intact [94]. The
requirement for AR in mediating the apoptotic effect of
MEKK1 apparently contrasted with the role of AR signalling
as a survival and/or proliferative factor in prostate secretory
epithelial cells. However, AR signalling has been detrimental
to PC growth and survival in certain settings (e.g., the effects
of high concentrations of androgen on the AR-positive
LNCaP cells or transfection of AR into AR-negative PC3 and
DU145 cells ) [98,99].
PI3K
Phosphorylation of phosphatidylinositol (PtdIn) at the D3
position by extracellular stimuli plays a major role in cell
survival. Through activation of protein kinases such as the
phosphoinositide-dependent protein kinases (PDK1 and
PDK2) and Akt /protein kinase B (Akt /PKB), PtdIn 3,4,5-
trisphosphate (PIP3) inhibits apoptosis and influences other
intracellular metabolic functions. Targets phosphorylated by
Akt include the proapoptotic proteins (e.g., BAD), caspase 9,
and the forkhead transcription factors as well as enzymes
involved in intracellular metabolism such as glycogen
synthase kinase-3 (GSK-3b ) [100–102] (Figure 1B ).
PTEN (phosphatase and tensin homologue deleted on
chromosome 10) is the negative downregulator of the PI3K
pathway acting as a PtdIn phosphatase. Loss of PTEN
function results in the constitutive activation of Akt. Tumor
cells affected in this manner may escape dependence on
extracellular survival factors and may becomemore resistant
to agents that induce apoptosis [103]. The increased
frequency of PTEN dysfunction and/or mutations in prostate
and other cancers underscores the potential importance of
signals provided by the PI3K/Akt pathway in the develop-
ment and proliferation of cancer cells [104–106].
The PI3K/Akt signalling axis has been described recently
as a dominant growth factor survival pathway in PC, which at
best can only be partially compensated by a MAPK-sensitive
step [107,108]. In the LNCaP PC model of AI, PI3K
signalling was activated at the onset of androgen deprivation
and progressively increased thereafter [107,109]. Androgen
ablation increased PI3K/Akt activation, possibly by promot-
ing the abnormal establishment of autocrine growth factor
loops and/or enhancing the engagement of already-present
growth factor signalling pathways [6,110] (Figure 2). PI3K
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promoted survival of the acute effects of androgen depriva-
tion and promoted proliferation of AI PC cells by diminishing
the expression of the cyclin -dependent inhibitor p27kip1
[111] and/or increasing its degradation [107]. ErbB2-
induced AR transactivation is mediated only partially through
the MAPK pathway and requires a functional PI3K/Akt
pathway [109]. Inhibition of PI3K signalling by dominant
negative Akt or the PI3K inhibitor LY294002 completely
abolished AR activation by ErbB2, whereas PD98059, an
MAPK inhibitor, inhibited it only partially [66,109]. Attenu-
ation of the PI3K/Akt pathway either by pharmacological
inhibitors or PTEN triggered a rapid and extensive apoptosis
in LNCaP cells [107,108,112,113]. This response could not
achieved by MAPK inhibition and was prevented by pretreat-
ment with androgens or growth factors [107,108,112,114].
The mechanism by which androgens can overcome the
apoptotic response to PI3K inhibition is yet unknown. It may
result from PI3K activation and/or PTEN inhibition and it
clearly involves the AR [108,114]. Some researchers
demonstrated that in AR-positive cells, DHT rapidly acti-
vated PI3K and increased intracellular PIP3 in an in vitro
kinase assay (Figure 1B ) [89,115], whereas others failed to
observe any effect of DHT on PI3K or PTEN [114,116].
Alternatively, androgens may protect from PTEN- induced
apoptosis either by activating a survival pathway that is
independent of Akt, or by activating the same survival
pathway at steps downstream of Akt [112,116]. PI3K/Akt
has been shown to be a key regulator of AR expression in
mouse vas deferens epithelial cells and in LNCaP cells.
Inhibition of the PI3K pathway strongly decreased both
basal and DHT- induced levels of AR [117]. Exposure of
LNCaP to LY294002 pretreatment inhibited the increased
expression of PSA mRNA normally induced by DHT
[117,118].
Protein Kinase B/Akt
Transfection of a constitutively active Akt maintains PC
survival in an androgen-poor or growth factor–poor environ-
ment [107,111]. In addition to its negative effects on the
proapoptotic machinery, some studies have demonstrated
that activated Akt specifically interacted with and phosphory-
lated both ERa (at Ser167) and AR (two sites): N- terminal
Ser210 and C-terminal Ser790 [109–121]. AR phosphor-
ylation by Akt was shown to promote PC survival, but
whether it activated or inhibited AR gene transcription was
unclear. Several groups have reported the activation of the
AR transcription by Akt in the absence of androgen
[109,114]. In support of the above findings, PTEN, the
negative regulator of the PI3K pathway, antagonized AR
signalling and androgen- induced cell proliferation and
repressed the transcriptional activity of the AR as well as
PSA production [114]. In contrast, Lin et al. [119] reported
that Akt inhibited androgen/AR–induced apoptosis and
blocked AR target genes such as p21, thereby promoting
PC survival. The constitutively active forms of PI3K or Akt
repressed the transactivation of AR and the interaction
between AR and its coactivators. Additionally, the phosphor-
ylation of AR by Akt appears to be critical for AR
ubiquitylation and subsequent degradation by the protea-
some [122]. This effect of Akt on AR was markedly reduced
if two serine residues (Ser210 and Ser790) were replaced
with alanine, preventing Akt induced AR phosphorylation, or
in a Mdm2-null cell line compared with the wild- type cell line
[122]. Other researchers have been unable to demonstrate
a physical protein–protein interaction between Akt and AR or
phosphorylation of AR by Akt in vitro [114,118]. They
proposed that b -catenin acted as a mediator in the crosstalk
between PI3K and androgen signalling [118]. PI3K/Akt
induced the phosphorylation and inactivation of GSK-3b,
Figure 2. A synopsis of the crosstalk between AR and the ErbB cascade. This figure provides a brief outline of the interplay of AR and ErbB cascade in promoting PC
survival. Growth factor signals augment AR survival signals and enhance AR transactivation through the MAPK /ERK, MEKK /JNKK/ c - Jun, and the PI3K /Akt
pathways. This enhancement is shown in vitro to occur both in the presence and absence of ligand. Apoptotic responses initiated by stress signals acting through
MEKK /JNKK /JNK and the AR can be subverted by activation of the PI3K /Akt pathway downstream of growth factors, thereby allowing PC cell survival.
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which in turn increased nuclear levels of b -catenin. Increased
b -catenin elevates AR activity, stimulating PC growth and
survival [118].
The interaction between the AR and the PI3K/Akt
pathway is summarized in Figure 1B and in Table 1.
Conclusion
The development of AI PC is one of the major problems in its
treatment. A shift in growth support from androgens to
growth factors may enhance the ability of PC cells to survive
the acute effects of androgen withdrawal and to proliferate in
androgen-depleted conditions. The continued expression of
AR and AR-regulated genes in AI PC suggests that
alternative signalling pathways are utilized to activate the
AR. Elements of the AR and ErbB pathways interact, cross
over, and converge on targets downstream of each other’s
signalling cascades to promote AI PC cell survival (sum-
marized in Table 1 and Figure 2). It is noteworthy to mention
that studies revealing AI mechanisms of AR activation have
been performed in vitro. Additionally and more importantly,
the ligand- free environment that is achievable in the
laboratory may not be reflected in the clinical situation
because very low levels of androgen remain in patients’
serum (castrate testosterone is defined as less than 50 ng/
dl ) despite surgical or pharmacologic castration.
Although manipulative in vitro data or descriptive in vivo
data have not yet resolved the mechanism of AI growth,
identification of these interactions and their physiological
relevance enhances understanding of the possible means by
which PC cells escape their requirement for androgen. This
understanding suggests that inhibition of these signalling
interactions could convert AI PC back to a hormone-
sensitive state and offers possible additional strategies in
the management of PC.
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